PRCT

Analyst Note: PROCEPT BioRobotics Corporation (PRCT)

Date: 2026-06-20 Current Price: $21.72

1. Structural Readiness

• Conservative Entry: Not yet actionable (awaiting confirmed breakout).
• Aggressive/Pre-Breakout Entry: $21.72 (Current Price).
• Breakout Level: Not yet established (requires price to close decisively above the current consolidation range).
• Current Price: $21.72.
• Extension: Not applicable (price is within the forming range, not extended above a breakout).
• ATR Context: Current ATR is 8.2% (Extreme). This indicates high volatility and significant risk of whipsaw during the formation phase. Historically, extreme ATR levels correlate with higher failure rates for setups that do not break out cleanly.

2. Thesis Layer

• Primary Secular Theme: Advanced Robotics & Humanoid → Industrial & Service Robots.
• *Directness:* Tier Direct. PRCT is a primary beneficiary, developing and selling image-guided surgical robotic systems (AquaBeam and HYDROS) that automate complex urologic procedures.
• Thesis Weighting: The company is a pure-play on the automation of minimally invasive surgery. While the "Humanoid" label in the secular list is broad, PRCT's specific role is in the "Service Robot" sub-sector (medical service), directly replacing manual resection techniques with robotic precision. The thesis is supported by the secular tailwind of an aging demographic (BPH prevalence) and the structural shift toward robotic-assisted procedures over traditional open surgery.

3. Business Overview

PROCEPT BioRobotics Corporation develops, manufactures, and sells advanced, image-guided, surgical robotic systems for minimally invasive urologic surgery, with an initial focus on treating Benign Prostatic Hyperplasia (BPH).

• Products: The company operates two primary systems: the AquaBeam Robotic System and the HYDROS Robotic System.
• Business Model: The company generates revenue through the sale of robotic systems (capital equipment) and recurring revenue from single-use disposable handpieces.
• Market Position & Evidence (as of 2026-06-20):
• Install Base: As of March 31, 2026, the global install base reached 971 systems (including 765 in the U.S.), up from 912 as of December 31, 2025 (E10, E17).
• Procedure Volume: The company completed approximately 12,200 U.S. procedures in Q1 2026 (E1).
• System Sales: In Q1 2026, the company sold 49 Hydros systems (including 2 replacements) (E2).
• Pricing Dynamics: Q1 2026 U.S. average selling prices (ASPs) for Hydros systems were approximately $485,000 (E3). However, management expects new U.S. system pricing to range between $450,000 and $460,000 for the remainder of 2026, reflecting a mix of individual accounts and large Integrated Delivery Networks (IDNs) (E6).
• Financial Performance: For the three months ended March 31, 2026, the company generated $83.1 million in revenue with a net loss of $31.6 million, compared to $69.2 million revenue and a $24.7 million net loss in the prior year quarter (E13).
• Full Year Guidance (Management Expectations): Management expects full-year 2026 total revenue to be $390 million to $410 million (27%–33% growth vs. 2025) and total U.S. procedures to be 60,000 to 64,000 (39%–48% growth) (E4, E5).
• Reimbursement: Medicare coverage for Aquablation therapy is established in all 50 states (effective 2021), and private payor coverage is estimated to reach 95% of men in the U.S. (E12, E23).

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company exhibits high revenue growth (projected 27-33% for 2026) and expanding procedure volumes, characteristic of a growth leader in the medical device sector. The business is scaling its install base and moving toward operational leverage, though it remains in a net loss position.
• Conviction Stack:
• Thesis Strength: High. The secular tailwind of an aging population (BPH affects ~40M men in the U.S.) and the shift to robotic surgery is structural and long-term (E9, E18, E19).
• Evidence Quality: Strong. Recent earnings transcripts and 10-K/10-Q filings provide concrete data on procedure counts, system sales, and ASPs (E1-E7, E10-E13).
• Structural Quality: Moderate. The company has sufficient liquidity to fund operations for at least the next 12 months (E14), and debt maturity is not immediate (Term Loan matures Oct 2027) (E15).
• Setup Readiness: Low to Moderate. The setup is currently "Forming" with an Extreme ATR of 8.2%. This volatility suggests the market is uncertain about the sustainability of the growth or the pricing pressure (ASP decline from $485k to ~$455k guidance). The setup is not yet "Confirmed" (breakout fired).
• Rerating Potential: Dependent on the ability to maintain procedure growth while managing ASP compression. The path to profitability is the key catalyst.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A confirmed breakout above the consolidation ceiling with volume, or a management upgrade to the 2026 procedure guidance range (e.g., raising the top end above 64,000).
• Gaps in Evidence:
• Profitability Timeline: While the company has cash for 12 months, the specific timeline to GAAP profitability is not detailed in the provided evidence, only the current net loss figures.
• International Expansion: The evidence focuses heavily on the U.S. market (95% private payor coverage, U.S. procedure counts). There is no specific evidence provided regarding international revenue growth or regulatory approvals outside the U.S. as of this date.
• WATER IV Study Results: The transcript mentions enrollment is nearing completion (expected by end of May 2026), but the *results* of the study are not yet in the evidence base as of June 20, 2026. This is a critical data point for future adoption.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) Strong procedural growth trajectory (12,200 Q1 procedures, 39-48% full-year growth guidance); 2) Established reimbursement landscape (100% Medicare, 95% private payor coverage); 3) Sufficient liquidity runway through next 12 months. Key risks: 1) Extreme volatility (8.2% ATR) creating high risk of false breakouts or whipsaws; 2) Pricing pressure (ASP guidance decline from $485k to $450-460k range); 3) Continued net losses with no defined path to profitability in evidence. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the extreme ATR and unconfirmed structural state. Expected path: Management expects revenue growth of 27-33% and procedure growth of 39-48% for 2026; the stock likely remains in a consolidation range until the WATER IV study results are released or a confirmed breakout occurs. Expected horizon: 3 to 6 months for structural confirmation or invalidation.